A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.

Evidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the effect of selenium supplementation on the risk of type-2 diabete...

Full description

Bibliographic Details
Main Authors: Margaret P Rayman, Gabrielle Blundell-Pound, Roberto Pastor-Barriuso, Eliseo Guallar, Holger Steinbrenner, Saverio Stranges
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3446875?pdf=render
id doaj-6fa0a48c7b514183a391979a8da17897
record_format Article
spelling doaj-6fa0a48c7b514183a391979a8da178972020-11-25T01:53:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0179e4526910.1371/journal.pone.0045269A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.Margaret P RaymanGabrielle Blundell-PoundRoberto Pastor-BarriusoEliseo GuallarHolger SteinbrennerSaverio StrangesEvidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the effect of selenium supplementation on the risk of type-2 diabetes in a population of relatively low selenium status as part of the UK PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study. Plasma adiponectin concentration, a recognised independent predictor of type-2 diabetes risk and known to be correlated with circulating selenoprotein P, was the biomarker chosen.In a randomized, double-blind, placebo-controlled trial, five hundred and one elderly volunteers were randomly assigned to a six-month intervention with 100, 200 or 300 µg selenium/d as high-selenium or placebo yeast. Adiponectin concentration was measured by ELISA at baseline and after six months of treatment in 473 participants with one or both plasma samples available.Mean (SD) plasma selenium concentration was 88.5 ng/g (19.1) at baseline and increased significantly in the selenium-treatment groups. In baseline cross-sectional analyses, the fully adjusted geometric mean of plasma adiponectin was 14% lower (95% CI, 0-27%) in the highest than in the lowest quartile of plasma selenium (P for linear trend = 0.04). In analyses across randomized groups, however, selenium supplementation had no effect on adiponectin levels after six months of treatment (P = 0.96).These findings are reassuring as they did not show a diabetogenic effect of a six-month supplementation with selenium in this sample of elderly individuals of relatively low selenium status.http://europepmc.org/articles/PMC3446875?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Margaret P Rayman
Gabrielle Blundell-Pound
Roberto Pastor-Barriuso
Eliseo Guallar
Holger Steinbrenner
Saverio Stranges
spellingShingle Margaret P Rayman
Gabrielle Blundell-Pound
Roberto Pastor-Barriuso
Eliseo Guallar
Holger Steinbrenner
Saverio Stranges
A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.
PLoS ONE
author_facet Margaret P Rayman
Gabrielle Blundell-Pound
Roberto Pastor-Barriuso
Eliseo Guallar
Holger Steinbrenner
Saverio Stranges
author_sort Margaret P Rayman
title A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.
title_short A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.
title_full A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.
title_fullStr A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.
title_full_unstemmed A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.
title_sort randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description Evidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the effect of selenium supplementation on the risk of type-2 diabetes in a population of relatively low selenium status as part of the UK PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study. Plasma adiponectin concentration, a recognised independent predictor of type-2 diabetes risk and known to be correlated with circulating selenoprotein P, was the biomarker chosen.In a randomized, double-blind, placebo-controlled trial, five hundred and one elderly volunteers were randomly assigned to a six-month intervention with 100, 200 or 300 µg selenium/d as high-selenium or placebo yeast. Adiponectin concentration was measured by ELISA at baseline and after six months of treatment in 473 participants with one or both plasma samples available.Mean (SD) plasma selenium concentration was 88.5 ng/g (19.1) at baseline and increased significantly in the selenium-treatment groups. In baseline cross-sectional analyses, the fully adjusted geometric mean of plasma adiponectin was 14% lower (95% CI, 0-27%) in the highest than in the lowest quartile of plasma selenium (P for linear trend = 0.04). In analyses across randomized groups, however, selenium supplementation had no effect on adiponectin levels after six months of treatment (P = 0.96).These findings are reassuring as they did not show a diabetogenic effect of a six-month supplementation with selenium in this sample of elderly individuals of relatively low selenium status.
url http://europepmc.org/articles/PMC3446875?pdf=render
work_keys_str_mv AT margaretprayman arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT gabrielleblundellpound arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT robertopastorbarriuso arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT eliseoguallar arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT holgersteinbrenner arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT saveriostranges arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT margaretprayman randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT gabrielleblundellpound randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT robertopastorbarriuso randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT eliseoguallar randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT holgersteinbrenner randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
AT saveriostranges randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin
_version_ 1724990725897060352